Boehringer Ingelheim has exercised an option for exclusive rights to an oncology target under an ongoing discovery collaboration with Oxford BioTherapeutics. The target was discovered using Oxford’s OGAP system, which incorporates one of the largest proteomic databases, integrating clinical, experimental and expression data.   This is the first option exercised under the oncology target discovery and validation collaboration established in 2013. Boehringer Ingelheim is responsible for the ...